These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Respiratory syncytial virus: babies and antibodies. Hemming VG; Prince GA Infect Agents Dis; 1992 Feb; 1(1):24-32. PubMed ID: 1365525 [No Abstract] [Full Text] [Related]
4. Anti-respiratory syncytial virus monoclonal antibodies show promise in the treatment and prophylaxis of viral disease. Taylor G; Porter T; Dillon S; Trill J; Ganguly S; Hart T; Davis C; Wyde P; Tempest P; Harris W Biochem Soc Trans; 1995 Nov; 23(4):1063-7. PubMed ID: 8654682 [No Abstract] [Full Text] [Related]
5. Respiratory syncytial virus (RSV) as a common cause of respiratory illness in children younger than 5 years. Poehling KA; Hickson GB Ambul Pediatr; 2003; 3(6):342-4. PubMed ID: 14616052 [No Abstract] [Full Text] [Related]
10. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Meissner HC; Long SS; Pediatrics; 2003 Dec; 112(6 Pt 1):1447-52. PubMed ID: 14654628 [TBL] [Abstract][Full Text] [Related]
12. Respiratory syncytial virus: different criteria for palivizumab use in different areas? Mitchell I South Med J; 2007 Jul; 100(7):661-2. PubMed ID: 17639741 [No Abstract] [Full Text] [Related]
13. The role of immunoprophylaxis in the reduction of disease attributable to respiratory syncytial virus. Meissner HC; Bocchini JA; Brady MT; Hall CB; Kimberlin DW; Pickering LK Pediatrics; 2009 Dec; 124(6):1676-9. PubMed ID: 19948632 [No Abstract] [Full Text] [Related]
14. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group. Groothuis JR; Simoes EA; Levin MJ; Hall CB; Long CE; Rodriguez WJ; Arrobio J; Meissner HC; Fulton DR; Welliver RC N Engl J Med; 1993 Nov; 329(21):1524-30. PubMed ID: 8413475 [TBL] [Abstract][Full Text] [Related]
15. The race to make vaccines for a dangerous respiratory virus. Powell K Nature; 2021 Dec; 600(7889):379-380. PubMed ID: 34893769 [No Abstract] [Full Text] [Related]
16. [Experience of palivizumab in prophylaxis of respiratory syncytial viral infection in premature children with bronchopulmonary dysplasia]. Aliamovskaia GA; Keshinian ES Vestn Ross Akad Med Nauk; 2012; (12):30, 32-4. PubMed ID: 23530423 [TBL] [Abstract][Full Text] [Related]
17. [Recommendations for immunologic prevention of respiratory syncytial virus (RSV) infections]. Z Geburtshilfe Neonatol; 1999 Dec; 203 Suppl 2():16. PubMed ID: 10612193 [No Abstract] [Full Text] [Related]
18. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn Pediatrics; 2003 Dec; 112(6 Pt 1):1442-6. PubMed ID: 14654627 [TBL] [Abstract][Full Text] [Related]